Literature DB >> 21320698

T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization.

Kristin L Moffitt1, Todd M Gierahn, Ying-jie Lu, Paulo Gouveia, Mark Alderson, Jessica Baker Flechtner, Darren E Higgins, Richard Malley.   

Abstract

Streptococcus pneumoniae is a leading cause of mortality in young children. While successful conjugate polysaccharide vaccines exist, a less expensive serotype-independent protein-based pneumococcal vaccine offers a major advancement for preventing life-threatening pneumococcal infections, particularly in developing nations. IL-17A-secreting CD4+ T cells (T(H)17) mediate resistance to mucosal colonization by multiple pathogens including S. pneumoniae. Screening an expression library containing >96% of predicted pneumococcal proteins, we identified antigens recognized by T(H)17 cells from mice immune to pneumococcal colonization. The identified antigens also elicited IL-17A secretion from colonized mouse splenocytes and human PBMCs suggesting that similar responses are primed during natural exposure. Immunization of two mouse strains with identified antigens provided protection from pneumococcal colonization that was significantly diminished in animals treated with blocking CD4 or IL-17A antibodies. This work demonstrates the potential of proteomic screening approaches to identify specific antigens for the design of subunit vaccines against mucosal pathogens via harnessing T(H)17-mediated immunity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320698      PMCID: PMC3061323          DOI: 10.1016/j.chom.2011.01.007

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  28 in total

1.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products.

Authors:  K A Datsenko; B L Wanner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

4.  LacZ inducible, antigen/MHC-specific T cell hybrids.

Authors:  S Sanderson; N Shastri
Journal:  Int Immunol       Date:  1994-03       Impact factor: 4.823

5.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Authors:  D E Briles; S K Hollingshead; J King; A Swift; P A Braun; M K Park; L M Ferguson; M H Nahm; G S Nabors
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

6.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

Authors:  G S Nabors; P A Braun; D J Herrmann; M L Heise; D J Pyle; S Gravenstein; M Schilling; L M Ferguson; S K Hollingshead; D E Briles; R S Becker
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

7.  Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection.

Authors:  T M Wizemann; J H Heinrichs; J E Adamou; A L Erwin; C Kunsch; G H Choi; S C Barash; C A Rosen; H R Masure; E Tuomanen; A Gayle; Y A Brewah; W Walsh; P Barren; R Lathigra; M Hanson; S Langermann; S Johnson; S Koenig
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae.

Authors:  A D Ogunniyi; R L Folland; D E Briles; S K Hollingshead; J C Paton
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

9.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae.

Authors:  David E Briles; Susan K Hollingshead; James C Paton; Edwin W Ades; Lea Novak; Frederik W van Ginkel; William H Benjamin
Journal:  J Infect Dis       Date:  2003-07-14       Impact factor: 5.226

View more
  90 in total

Review 1.  Next generation pneumococcal vaccines.

Authors:  Kristin L Moffitt; Richard Malley
Journal:  Curr Opin Immunol       Date:  2011-04-21       Impact factor: 7.486

Review 2.  Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors:  Richard Malley; Porter W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

3.  Identification of genes that contribute to the pathogenesis of invasive pneumococcal disease by in vivo transcriptomic analysis.

Authors:  Abiodun D Ogunniyi; Layla K Mahdi; Claudia Trappetti; Nadine Verhoeven; Daphne Mermans; Mark B Van der Hoek; Charles D Plumptre; James C Paton
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

4.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

Authors:  Weihui Wu; Jin Huang; Biyan Duan; David C Traficante; Haeyeon Hong; Martina Risech; Stephen Lory; Gregory P Priebe
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

Review 5.  Large screen approaches to identify novel malaria vaccine candidates.

Authors:  D Huw Davies; Patrick Duffy; Jean-Luc Bodmer; Philip L Felgner; Denise L Doolan
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

Review 6.  Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.

Authors:  Hsing-Chuan Tsai; Reen Wu
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

7.  MicroRNA-155 is required for clearance of Streptococcus pneumoniae from the nasopharynx.

Authors:  Chris P Verschoor; Michael G Dorrington; Kyle E Novakowski; Julie Kaiser; Katherine Radford; Parameswaran Nair; Varun Anipindi; Charu Kaushic; Michael G Surette; Dawn M E Bowdish
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 8.  Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets.

Authors:  Lok-To Sham; Ho-Ching T Tsui; Adrian D Land; Skye M Barendt; Malcolm E Winkler
Journal:  Curr Opin Microbiol       Date:  2012-01-24       Impact factor: 7.934

9.  Strain-specific regulatory role of eukaryote-like serine/threonine phosphatase in pneumococcal adherence.

Authors:  Shivangi Agarwal; Shivani Agarwal; Preeti Pancholi; Vijay Pancholi
Journal:  Infect Immun       Date:  2012-02-06       Impact factor: 3.441

10.  Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization.

Authors:  Leen Moens; Philippe Hermand; Tine Wellens; Greet Wuyts; Rita Derua; Etienne Waelkens; Carine Ysebaert; Fabrice Godfroid; Xavier Bossuyt
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.